首页 › 多发性骨髓瘤 › 阿拉巴马州 › Birmingham
Birmingham AL 多发性骨髓瘤临床试验
17项针对 多发性骨髓瘤的研究正在 Birmingham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- University of Alabama Birmingham, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- University of Alabama at Birmingham, Birmingham
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
招募中1/2 期
- University of Alabama At Birmingham Hospital, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- University of Alabama at Birmingham, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Alabama Oncology, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
招募中1/2 期
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1/2 期
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
招募中2 期
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
招募中2 期
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
招募中
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
招募中观察性研究
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
招募中1/2 期
- UAB Comprehensive Cancer Center, Birmingham
其他城市的 多发性骨髓瘤试验
- New York City, NY59 项研究
- Boston, MA45 项研究
- Atlanta, GA42 项研究
- Houston, TX39 项研究
- Durham, NC36 项研究
- Nashville, TN31 项研究
- Denver, CO26 项研究
- St. Louis, MO26 项研究
- Rochester, MN25 项研究
- Columbus, OH25 项研究
- Chicago, IL24 项研究
- Milwaukee, WI23 项研究
Birmingham的其他研究
- 癌症（所有类型）30 项研究
- 卵巢癌25 项研究
- 乳腺癌24 项研究
- 非小细胞肺癌23 项研究
- 肥胖症22 项研究
- 急性髓系白血病21 项研究
- 慢性阻塞性肺病17 项研究
- 心血管疾病16 项研究
- 子宫内膜癌16 项研究
- 超重16 项研究
- 2型糖尿病16 项研究
- 囊性纤维化15 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。